Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-1403+ additive coformulation · 1 trial · 1 indication
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs will be reported.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| Panel A MK-1403 + additive coformulation dose 1 | EXPERIMENTAL | Participants will receive MK-1403 + additive coformulation dose 1 orally once daily. |
| Panel A Placebo + additive coformulation dose 1 | PLACEBO_COMPARATOR | Participants will receive Placebo + additive coformulation dose 1 orally once daily. |
| Panel B MK-1403 + additive coformulation dose 2 | EXPERIMENTAL | Participants will receive MK-1403 + additive coformulation dose 2 orally once daily |
| Panel B Placebo + additive coformulation dose 2 | PLACEBO_COMPARATOR | Participants will receive Placebo + additive coformulation dose 2 orally once daily |
| Name | Type | Description |
|---|---|---|
| MK-1403 + additive coformulation | DRUG | MK-1403 + additive coformulation is a co-formulated product of MK-1403 administered orally. |
| Placebo + additive coformulation | DRUG | Placebo + additive coformulation is a co-formulated product of placebo administered orally. |
Inclusion Criteria: * Has a confirmed diagnosis of Type 2 diabetes mellitus (T2DM) * Has body mass index (BMI) between 18 and 40 kg/m\^2, inclusive Exclusion Criteria: * Has Type 1 diabetes mellitus or secondary types of diabetes * Has a history of congestive heart failure (New York Heart Associa...
MK-1403 + additive coformulation is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
MK-1403 + additive coformulation is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate this investigational therapy.
MK-1403 + additive coformulation is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing trial is active but not recruiting participants.
MK-1403 + additive coformulation is being studied in one active Phase 1 trial, NCT07242469, titled "A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)." This randomized, double-blind, placebo-controlled trial is enrolling 52 participants in the United States.
MK-1403 + additive coformulation is also known as MK-1403 + additive coformulation. The trial title refers to MK-1403, and the coformulation includes an additive component. No other alternative names have been disclosed.